美国制药商辉瑞周三表示,将从所有获批的市场撤回其镰状细胞病治疗药物Oxbryta,还将停止所有正在进行的Oxbryta的临床试验和全球扩展访问计划。公司表示,预计此次撤药不会影响其2024年全年财务前景。辉瑞在一份声明中表示,辉瑞的决定是基于临床数据,这些数据表明Oxbryta在SCD患者中的总体益处不再高于风险。数据表明,患者的血管闭塞危象和致命事件已失衡,需要进一步评估。Oxbryta是辉瑞...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.